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1. INTRODUCTION 
The bactericidal action of moxifloxacin results from 
inhibition of the enzymes topoisomerase II (DNA 
gyrase) and topoisomerase IV. DNA gyrase is an 
essential enzyme that is involved in the replication, 
transcription and repair of bacterial DNA. 
Topoisomerase IV is an enzyme known to play a key 
role in the partitioning of the chromosomal DNA during 
bacterial cell division. Difluprednate is a topical 
corticosteroid indicated for the treatment of infammation 
and pain associated with ocular surgery. This 
combination of drugs will be used to treat optical 
infections. 
The literature is enriched with several methods for 
determination of MOX and DIFLU in pharmaceutical 
dosage forms either as a single drug or in combination 
with some other drugs. The most extensively used 
technique for estimation of MOX are by UV3-6,      
HPLC7-14, and UPLC15 methods and most extensively 
used technique for estimation of DIFLU is by HPLC16. 
The aim of study is development and Validation of 
Analytical HPLC method for Simultaneous Estimation of 
Moxifloxacin and Difluprednate in their combimed 
Dosage form. 
The present study was designed to develop a simple, 
precise, and rapid analytical RP-HPLC procedure, which 
can be used for the analysis of assay method for 
simultaneous estimation of Moxifloxacin and 
Difluprednate as there was only individual methods 
reported for both drugs. The combination of these two 
drugs is not official in any pharmacopoeia; hence no 
official method is available for the simultaneous 
estimation of these two drugs in their combined dosage 
forms. Literature survey of Moxifloxacin and 
Difluprednate revealed several methods for detecting 
these drugs individually but there is no method for their 
simultaneous estimation using RP-HPLC. 
 
FIGURE 1: Chemical structure of Moxifloxacin 
 
FIGURE 2: Chemical structure of Difluprednate 
 
*Address for correspondence 
Prasanna Kumar Pradhan 
Sigma institute of pharmacy, 
Bakrol, Vadodara. 
(m) 08141865430 
E mail id:  prasanna.k.pradhan@gamil.com
ABSTRACT 
Moxifloxacin is synthetic fluoroquinolone antibiotic agent and Difluprednate is a topical corticosteroid indicated for the 
treatment of infammation and pain associated with ocular surgery. This combination of drugs will be used to treat optical 
infections. In RP-HPLC method, a mobile phase of Phosphate Buffer (pH 3.5) : Methanol (35:65 v/v)  was used to resolve 
Moxifloxacin and Difluprednate from a mixture. The linearity range obtained for the HPLC method were 25 - 75 μg/ml and 2.5 
– 7.5 μg/ml with corresponding correlation coefficient of 0.998 and 0.997, for Moxifloxacin and Difluprednate respectively. 
Flow rate was set to 1 ml/min and detection was carried out at 244 nm. The method was found to be rapid, accurate and 
precise. This method was validated according to ICH guidlines. 
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2. MATERIAL AND METHODS 
2.1 Apparatus and Instrument 
The analysis was carried out on a HPLC system 
(Shimadzu LC-20- AT) equipped with UV detector. 
Other apparatus and instruments used were a micro 
analytical balance (Shimadzu),  Ultrasonic Cleaner (EIE 
Instruments Pvt. Ltd. Ahmedabad), Nylon Membrane 
Filters (0.22mcm, 47 mm D). All instruments and glass 
wares were calibrated. 
2.2 Reagents and Materials 
Moxifloxacin and Difluprednate were obtained as gratis 
sample from Accurate Pharmaceuticals, Godhra. 
Methanol HPLC Grade, Water HPLC Grade, Phosphate 
Buffer , O-Phosphoric Acid were used which were 
obtained from Samir Tech-Chem Pvt. Ltd. A stock-
standard solution of MOX and DIFLU was prepared by 
dissolving accurately weighed amount of pure drug in 
mobie phase. 
2.3 Mobile Phase: Phosphate Buffer (pH 3.5) : 
Methanol(35:65 v/v). The mobile phase was filtered 
through Millipore filter paper type HV (0.45 µm) and 
degassed by sonication. 
2.4 Chromatographic conditions 
Chromatographic analysis was carried out on an an 
inertsil C-18 column, (5 µm, 250mm x 4.6mm i.d) LC-
20 AT. The mobile phase consisted of Phosphate 
Buffer(pH 3.5) : Methanol(35:65 v/v). The mobile phase 
was filtered through Millipore filter paper type HV (0.45 
µm) and degassed by sonication, was pumped at 1.0 
ml/min flow rate. The column was thermostated at room 
temperature. Under these conditions the runtime was 10 
min. 
2.4.1 Preparation of standard stock solution of MOX 
(500 μg/ml) and DIFLU (50μg/ml) 
A 50 mg of standard MOX and 5 mg of standard DIFLU 
was weighed and transferred to a 100 ml volumetric flask 
each and dissolved in 25 ml mobile phase. The flask was 
shaken and volume was made up to the mark with 
mobile phase to give a solution containing 500 μg/ml 
MOX and 50 μg/ml of DIFLU. 
2.4.2 Preparation of combined working standard 
solution containing MOX and DIFLU in ratio of 10:1 
Accurately weighed 50 mg MOX and 5 mg of DIFLU 
were transferred to 100 ml volumetric flask, dissolved in 
sufficient amount of mobile phase and diluted up to mark 
with mobile phase to get concentration of 500 μg/ml 
MOX and 50 μg/ml DIFLU. This solution was diluted 
further to get the concentrations in range of 25, 37.5, 50, 
62.5, 75 μg/ml Moxifloxacin and 2.5, 3.75, 5.0, 6.25, 7.5 
μg/ml Difluprednate. 
2.5 Method Validation 
2.5.1 Precision 
Repeatability: Precision of the method was studied by 
making repeated injections of the mixture of drugs on the 
same day for intraday precision.The %RSD after six 
determinations was determined at 50 µg/ml for MOX 
and 5 µg/ml for DIFLU. 
Intraday and Interday Precision: Intraday and Interday 
precision for method were measured in term of %RSD. 
The experiment was repeated three times in a day for 
intraday and on three different days for interday 
precision by taking small, middle and higher 
concentration of MOX(25, 50, 75 µg/ml) and 
DIFLU(2.5, 5.0, 7.5 µg/ml). 
2.5.2 Linearity: The linearity of measurement was 
evaluated by analyzing standard solutions of MOX and 
DIFLU in the range of 25–75 µg/ml and 2.5-7.5 µg/ml 
for both drugs respectively and calibration plot was 
constructed. 
2.5.3 Limit of Detection (LOD) and Limit of 
Quantitation (LOQ): 
LOD and LOQ of MOX and DIFLU were determined by 
calibration curve method. Solutions of Moxifloxacin and 
Difluprednate were prepared in the range of 25–75 µg/ml 
and 2.5-7.5 µg/ml for both drugs respectively and 
injected in triplicate. 
2.5.4 Accuracy: Accuracy of the method was calculated 
by recovery studies at three levels by standard addition 
method, which is, spiking about 80%, 100%, 120% of 
MOX and DIFLU to the standard solutions containing 25 
µg/ml of MOX and 2.5 µg/ml of DIFLU. 
2.5.5 Robustness: Influence of small changes in 
chromatographic conditions such as change in flow rate, 
that is, ±0.2 ml/min, mobile phase composition  ±2 ml 
and pH ±0.2 was studied to determine the robustness of 
the method for the development of RP-HPLC method for 
the simultaneous estimation of MOX and DIFLU and 
their %RSD was determined. 
2.5.6 System Suitability: The stock solution containing 
50 µg/ml of MOX and 5 µg/ml of DIFLU was injected 
and repeated five times and the chromatograms were 
recorded.The resolution, number of theoretical plates, 
and peak asymmetry were calculated to determine 
whether the result complies with the recommended limit. 
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3. RESULTS AND DISCUSSION 
 
FIGURE 3: Chromatogram of MOX and DIFLU respectively 
3.1 Optimization of Chromatographic conditions 
To optimize the chromatographic conditions for 
separation of Moxifloxacin and Difluprednate, mobile 
phase composition, the effect of temperature and 
wavelength of detection investigated. 
During the method development work, enable C18 
column (25 cm× 4.6 mm i.d.) with particle size of 5 µm 
was used and gave the suitable resolution. The mobile 
phase composition was prepared with appropriate 
proportion of phosphate buffer (Ph 3.5) : Methanol 
(35:65 v/v).  
It was shown that the most efficient resolution and peak 
symmetry for Moxifloxacin and Difluprednate with a 
mobile phase composed of phosphate buffer (Ph 3.5) : 
Methanol (35:65 v/v) and a flow rate of 1 ml/min. The 
retention time for Moxifloxacin and Difluprednate were 
found to be 3.99 and 6.637 min respectively.  
The wavelength selected was from the overlay of 
Moxifloxacin and Difluprednate. Both the drugs showed 
typical peak nature and peaks were symmetrical at 244 
nm. Hence the wavelength has been selected as the 
detection wavelength. 
3.2 Validation 
3.2.1 Linearity and Range 
The linearity of measurement was evaluated by 
analyzing standard solutions of MOX and DIFLU in the 
range of 25–75 µg/ml and 2.5-7.5 µg/ml respectively for 
both drugs and calibration plot was constructed. 
 
TABLE 1: Statistical Parameter for Moxifloxain and Difluprednate 
Statistical Parameter Moxifloxacin Difluprednate 
Average peak area* ± SD  2245.07 ± 1.54 1882.85 ± 1.73 
3141.42  ± 1.56 2602.19 ± 1.66 
4342.16 ± 1.58 3641.42 ± 1.65 
5378.89 ± 1.14 4510.82 ± 1.58 
6432.78 ± 1.80 5394.70 ± 1.51 
Concentration Range (µg/ml) 25-75 2.5-7.5 
Straight line equation y =  84.903x + 62.919 y = 714.59x + 33.467 
Correlation coefficient (R
2
) 0.998 0.997 
LOD (μg/ml) 2.83 0.35 
LOQ (μg/ml) 8.57 1.07 
*n=5 
 
 
FIGURE 4: Calibration curve of Moxifloxacin 
 
FIGURE 5: Calibration curve of Difluprednate
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3.2.2 Precision 
Precision of the method was studied by making repeated 
injections of the mixture of drugs. The Relative Standard 
Deviation (%RSD) after six determinations was 0.67% at 
50 μg/ml for MOX and 1.23% at 5 μg/ml for DIFLU (see 
Table 2).  
 
TABLE 2: Precision data for MOX and DIFLU 
Precision Concentration found* (μg/ml) %RSD 
MOX DIFLU MOX DIFLU 
Repeatibility 50.07 4.93 0.57 0.86 
Intraday Precision 25.01 2.51 0.69 1.12 
50 5.01 1.16 1.37 
75.99 7.59 0.49 1.24 
Interday Precision 25 2.51 0.79 1.55 
49.99 5.01 0.69 1.70 
75.01 7.5 0.30 0.81 
*n=6 
3.2.3 LOD and LOQ 
LOD and LOQ of MOX and DIFLU were determined by 
calibration curve method. Solutions of MOX and DIFLU 
were prepared in the range of 25–75 μg/ml and 2.5-7.5 
μg/ml respectively and injected in triplicate (see Table 
1). 
3.2.4 Accuracy 
Accuracy of the method was calculated by recovery 
studies at three levels by standard addition method. The 
mean percentage recoveries obtained for MOX and 
DIFLU were 99.59% and 99.72%, respectively (see 
Table 3).  
 
TABLE 3: Recovery data for MOX and DIFLU 
Diflumox Eye 
Drops 
Conc. in eye 
drops (μg/ml) 
Conc. added 
(μg/ml) 
Total conc. 
found (μg/ml) 
Amount 
recovered 
(μg/ml) 
Mean Recovery* 
± SD 
(%) 
Moxifloxacin 25 20 44.99 19.99 99.61 ± 0.79 
25 25 49.90 24.90 99.57 ± 0.53 
25 30 54.90 29.90 99.59 ± 0.41 
Difluprednate 2.5 2 4.47 1.97 99.92 ± 0.64 
2.5 2.5 4.99 2.49 99.63 ± 0.65 
2.5 3 5.49 2.99 99.63 ± 0.49 
*n=3 
3.2.5 Robustness 
The method for the development of RP-HPLC method 
for the simultaneous estimation of MOX and DIFLU was 
found to be robust as the % RSD was found to be less 
than 2 (see Table 4) 
 
TABLE 4: Robustness data for MOX and DIFLU 
Parameters 
 
Variation % RSD 
MOX DIFLU 
 
Flow rate 
 
1.2 0.80 1.64 
(1 ml/min) 0.56 0.85 
0.8 0.88 1.59 
 
 
Mobile phase 
(37:63) 1.22 0.66 
Phosphate buffer pH 3.5 : Methanol (35:65) 0.56 0.85 
(33:67) 0.83 1.77 
 
 
pH (3) 
(3.2) 1.21 1.74 
pH (3) 0.56 0.85 
(2.8) 0.95 0.38 
 
3.2.6 System Suitability 
The resolution, number of theoretical plates, and peak 
asymmetry were calculated for the standard solutions. 
The stock solution containing 50 μg/ml of MOX and 5 
μg/ml of DIFLU was injected and repeated five times 
and the chromatograms were recorded. The resolution, 
number of theoretical plates, and peak asymmetry were 
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calculated to determine whether the result complies with the recommended limit (see Table 5) 
 
TABLE 5: System Suitability Parameters 
 
Parameters 
Drugs 
MOXIFLOXACIN DIFLUPREDNATE 
Retention Time (min) 3.99 6.367 
Resolution (Rs) 8.391 
Tailing Factor (t) 1.34 1.54 
No. of theoretical plates 4500 6008 
 
TABLE 6: Summary of Validation Parameter: 
Sr. No. Parameters Results 
MOXIFLOXACIN DIFLUPREDNATE 
1. Linearity Range (n=5) (μg/ml) 25-75 2.5-7.5 
2. Regression equation y = 84.903x + 62.919 y = 714.59x + 33.467 
3. 
Correlation coefficient (R
2
) 
0.998 0.997 
4. Limit of detection (n=5) (μg/ml) 2.83 0.35 
5. Limit of quantification (n=5) 
(μg/ml) 
8.57 1.07 
6. Precision   
Repeatability (%RSD) (n=6) 0.57 % 0.86 % 
Intraday (%RSD)(n=3) 0.78 % 1.24 % 
Interday (%RSD)(n=3) 0.59 % 1.35 % 
7. Robustness (%RSD) (n=3) 0.985 % 1.303 %  
8. Accuracy ( Mean ± SD)  
(%, n=3) 
99.59 ± 0.57 99.72 ± 0.59 
 
3.3 Procedure for the analysis of Eye Drops: 
Sample: Moxifloxacin and Difluprednate 
Brand name: DIFLUMOX  (Moxifloxacin 5%, 
Difluprednate 0.5%) 
Manufacturer: Ajanta Pharma Ltd, Mumbai, 
Maharashtra, India. 
3.3.1 Preperation of sample solution: 
DIFLUMOX eye drops containing 5 % of MOX and 0.5 
% of DIFLU is available in local market which is 
marketed by Ajanta Pharma(Mumbai). It contains 50 mg 
of MOX and 5 mg of DIFLU per ml. For preparation of 
stock solution, 1 ml from the suspension was taken in 10 
ml volumetric flask and diluted up to 10 ml with mobile 
phase. Then it was filtered through whatman filter paper 
(0.45μ). It was concentration of 5000 μg/ml of MOX and 
500 μg/ml of DIFLU. From that 1 ml of aliquots was 
taken and diluted up to 10 ml for getting concentration of 
500 μg/ml of MOX and 50 μg/ml of DIFLU. From this 
stock solution, working standard solution of 50 μg/ml of 
MOX and 5 μg/ml of DIFLU was prepared by taking 1 
ml and diluted it up to 10 ml with mobile phase. This 
solution was used for the estimation of MOX and DIFLU 
in their combined dosage form. 
 
TABLE 7: Analysis of market formulation 
Drug Label claim 
(%) 
Conc. 
taken for % 
Assay (μg/ml) 
Average 
Peak 
Area* 
 
Conc. 
found from 
Mixture as per labe1 claim 
(%) 
Assay* ± SD 
(%) 
 
Moxifloxacin 5 50 4453.85 4.93% 98.60 ± 0.74 
Difluprednate 0.5 5 3825.01 0.504% 100.98 ± 1.20 
*n=3 
CONCLUSION 
The proposed RP-HPLC method was used for the 
simultaneous estimation of Moxifloxacin and 
Difluprednate was found to be sensitive, accurate, 
precise, simple, and rapid. Hence the present     RP-
HPLC method may be used for routine analysis of the 
raw materials as well as combined dosage formulations 
containing Moxifloxacin and Difluprednate. 
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